Two Treatment Two Period

Crossover Design For Recurring

Disease

Semester IV Project

M.Sc. Statistics

*Souvik Saha*

*Sourav Saha*

Presidency University

*&*

*Aishani Barman Roy*

University of Kalyani

ABSTRACT

Crossover design is an important field in clinical trials. Majority of the works have been performed in cases of dichotomous or binary responses as well as continuous responses. This project emphasizes upon a crossover design of recurrence of any disease over two periods, considering two treatments, having carryover effects and involving count data responses. This project brings into limelight the creation of a statistical model for the crossover design and performing the necessary estimation and hypothesis testing to make some inferences about the effectiveness of our model upon implementation for the crossover design and draw some conclusions.

Keywords: Crossover design, Carryover effect, Statistical model, estimation, hypothesis testing, count data responses.

INTRODUCTION

A crossover design is a repeated measurements design such that each experimental unit (patient) receives different treatments during the different time periods, that is, the patients cross over from one treatment to another during the course of the trial. This is in contrast to a parallel design in which patients are randomized to a treatment and remain on that treatment throughout the duration of the trial. To clearly understand what a crossover design is, we have to know what actually happens in a crossover design. In a crossover design, each participant is randomized to a sequence of two or more treatments therefore the participant is used as his or her own control. Moreover, these subjects or participants receive these treatments over several study periods.

The reason to consider a crossover design when planning a clinical trial is that it could yield a more efficient comparison of treatments than a parallel design, that is, fewer patients might be required in the crossover design in order to attain the same level of statistical power or precision as a parallel design. Intuitively, this seems reasonable because each patient serves as their own matched control. Every patient receives both treatment A and B. Crossover designs are popular in medicine, agriculture, manufacturing, education, and many other disciplines.

There have been several works previously done in the area of crossover design, majority of which have been for dichotomous or binary responses. To name a few, works are done: - by U.Bandyopadhyay, A.Biswas, and S.Mukherjee (2007, 2009); by UttamBandyopadhyay, Atanu Biswas, Shirsendu Mukherjee (2011); among many others. Many of the works have also been for continuous responses. To name a few, they are: - by Uttam Bandyopadhyay &Shirsendu Mukherjee (2015); among many others. Moreover, there have been a few works in the area of crossover design for count data responses, namely, by M. W. J. Layard and J. N. Arvesen (1978); among few others. But statistical modeling of crossover design in count data response is very rare in past works. In this project, we are working upon building a statistical model for crossover design in count data responses since it is not unnatural or inapplicable even if it is rare and no past literature is present on modeling in crossover design for count data responses.

Thus, as suggested earlier, in our project, we develop a statistical model for crossover design of recurrence of any disease based on count data responses. The layout of our project is as follows: Section 2 deals with detail of the problem handled and the statistical modeling used. The inferential aspects, mainly estimation and hypothesis testing, are discussed elaborately in Section 3. Section 4 deals with detailed simulation study and display of related power curves. Finally, Section 5 concludes our project.

SECTION:-2

STATEMENT OF THE PROBLEM AND UNDERLYING MODEL

In this problem we are dealing with a two treatment two period pure crossover design for recurring disease with count response.

Here we consider two treatments A and B.

Then the possible combinations are AA,BB,AB,BA but since it is pure AA and BB is not considered.

Here KK’ states the combination in which the treatment K is in the first period and K’ is in the second period.

We are dealing with the number of recurrences of the disease in a population of N individuals both in the first and second periods and modelling them as follows:-

Let, K = A, B; KK’ = AB, BA

Let, Xk = number of recurrence of a chronic disease with treatment K in the first period.

Xkk’ = number of recurrence of a chronic disease with treatment K’ in the second period, provided treatment K(≠K’) was applied in first period.

Let, U : prognostic variant or covariate, assumed to remain same for a patient in both periods, like age, sex, some genotype etc.

Also suppose U assumes G+1 ordinal categories with scores 0, 1,….., G; i.e. U is assumed to be ordinal categorical variable with, P[ U = u ] = πu say, such that,

Assuming that higher value (level) of U restricts a treatment to perform satisfactorily, i.e. higher value (level) of U reduces effect of a treatment we propose probability models as,

1. Xk|U = u ~ Poisson with, E(Xk|U = u) = λk *a*G - u , where *a* is a known prognostic index, 0<*a*<1.
2. Xkk’|Xk = xk, U = u ~ Poisson with,

Some realizations about these probability models:

1. E(Xk) = E E(Xk|U) = λk π where, π = E[*a*G - u] =

=>E(Xkk’) = λkk’π

1. If Nk patients are assigned to treatment k in first period, k=A,B

Then, NA + NB = N, N : prefixed number

|  |
| --- |
| 1 if ith patient is assigned to treatment k  0 if else |

Define, δki =

Then the joint distribution will be,

, θ = λA,λB,λAB,λBA

SECTION 3:-INFERENTIAL PROCEDURES

**ESTIMATION OF PARAMETERS**

Define, Sk = and Skk’ =

Also, note that, Nk =

Now, E(Sk|*ḓ*k) = = λk π = λk π Nk

Var(Sk|*ḓ*k) = =

E(Skk’) = = λkk’ π = λkk’ π Nk

Var(Skk’) = = E Var(Xkk’|Xk,U) + Var E(Xkk’|Xk,U)

Again,

are the consistent estimators of λk and λkk’ respectively.

To avoid their estimates to be 0, we adjust the estimates as follows:

, where, and Nk

,

where, and Nk

Now,

Again,

where, Nk

So, where,

Since, this asymptotic distribution does not depend on allocation (n), we describe the procedures under NA = NB = n i.e. N/2 = n.

Define:-

log and log , k=A,B and k=AB,BA where is the main effect due to treatment k and is the period effect. No carryover effect is present in the model by assuming sufficiently large washout.

**Testing of Hypotheses**

To access which of the two treatments is better we suggest the following tests.

Test 1:-

Suppose we want to test the following hypotheses:-

: effects of two treatments are same

versus : treatment A is superior to treatment B

i.e : = versus :>.

Now,

log -log =-

Again log -log =-

-=

=

=( , , , )

Using Delta Method (first order) we get

E[( , , )] ,=-

V[( , , )]

V()+V()+V()+V()+2Cov(,)()()+ 2Cov(,)()()

=]

=. ,say

)

Under ,

and .

, and .

So under ,

= + + =(say)

With equal allocation weight that is with =,

= and =

So under,

as N

where

= ,

Here and

We reject the null hypotheses at 5% level of significance if .

TEST-2:-

Suppose the test is presented as

, vs , with strict inequality in atleast one case.

Now,

)

Under  **,**

)

Define:-

and

Then

N where

Using the approach as in Chatterjee and De(1972) we define the following test through the test statistic :-

,

= ,

= ,

We reject in favour of at level of significance if

Where c=c() is either obtained by simulation or by using Table 2.1 of Chatterjee and De(1972).

TEST-3:-

Using Multiple Testing Procedure(MTP) we define a third test statistic as follows:-

=max{

Now the critical region for testing , vs , with SIFAO case will be:-

where is obtained from size condition using Monte Carlo simulation.

Section 4:- Simulation Study

We work with a simulated data and based on that we get the power and standard error for the test statistics under different parameter choices.Then we plot the power curves of the three aforementioned tests for different sample sizes and parametric choices and study the properties.

For the parametric choice (λA,λB,λAB,λBA) = (2,2.5,1.5,1.3) and sample sizes (80,100,120,150,200,300) :

> power

[,1] [,2] [,3]

[1,] 0.1808 0.6358 0.3926


[2,] 0.2397 0.7139 0.4518

[3,] 0.3011 0.7836 0.5024

[4,] 0.3859 0.8491 0.6008

[5,] 0.5464 0.9376 0.7275

[6,] 0.7736 0.9883 0.8876



For the parametric choice (λA,λB,λAB,λBA) = (1.6,2.2,1.4,1.2) and sample sizes (80,100,120,150,200,300) :

> power

[,1] [,2] [,3]

[1,] 0.3137 0.7837 0.5489


[2,] 0.4106 0.8572 0.6294

[3,] 0.4986 0.9102 0.6979

[4,] 0.6100 0.9512 0.7991

[5,] 0.7771 0.9868 0.9025

[6,] 0.9380 0.9992 0.9816



For the parametric choice (λA,λB,λAB,λBA) = (2.9,3.3,2.7,2.3) and sample sizes (80,100,120,150,200,250,300) :

> power

[,1] [,2] [,3]

[1,] 0.1953 0.5484 0.3194

[2,] 0.2648 0.6277 0.3641


[3,] 0.3253 0.6960 0.3994

[4,] 0.4180 0.7662 0.4926

[5,] 0.5754 0.8784 0.6198

[6,] 0.7042 0.9266 0.6902

[7,] 0.7959 0.9625 0.7831



**REMARKS:-**

In the above power matrices the rows indicates the respective sample sizes and the columns indicate the tests.

1)With the increase in sample sizes the power of all the three tests are tending to 1 which indicates that all the three tests are consistent.

2)The tests involving the statistics T2 and T3 performs comparatively better than T1 with T2 being the best.

CONCLUSION

In our project, if we observe our simulation study, we have performed simulation work for known β. We tried the same for unknown β but could not complete it. So, we would eagerly want to venture the aspect of unknown β in our future work.

Moreover, in our project, we have assumed equal number of allocation of patients for application of both the treatments. So we would eagerly want to venture the aspect of random allocation of patients for application of both the treatments for our crossover design in the near future.

Similarly, we have considered the treatment combinations AB, BA after carryover to the second period. In the near future, we would want to take up the other possible combinations namely AA and BB and perform the similar tasks in the hope of getting better results.

Our proposed model can easily be generalized for more than two periods but its practical usefulness would much less than two period crossover design. So, at present, we do not discuss it in detail but we would definitely venture it in near future.

Moreover, we would also want to venture the possibility of more than two treatments in two or more periods in the near future.

ACKNOWLEDGEMENT

I express my sincere gratitude to the Department of Statistics, Presidency University, Kolkata and Dr. Saurav De,Assistant Professor, Department of Statistics, Presidency University, Kolkata in particular for his guidance and advise.I would also like to thank my partners for their support and assistance.

REFERENCES

1. U.Bandyopadhyay, A.Biswas and S.Mukherjee (2009). Adaptive two-treatment two-period crossover design for binary treatment responses incorporating carry-over effects. Statistical Methods & Applications, 18(1), pp.13-33.
2. Bandyopadhyay, U., Biswas, A., and Mukherjee, S. (2007). Adaptive two-treatment two-period crossover design for binary treatment responses.Statistica Neerlandica, Volume61, Issue3, August 2007, Pages 329-344.
3. UttamBandyopadhyay, AtanuBiswas, ShirsenduMukherjee (2011).Some inferential procedures in randomized repeated measurement design for binary response. Journal of the Korean Statistical Society, Volume 40, Issue 3, September 2011, Pages 245-255.
4. Uttam Bandyopadhyay &Shirsendu Mukherjee (2015). Adaptive Crossover Design for Normal Responses. Communications in Statistics - Theory and Methods, Volume 44, 2015 - Issue 7, Pages 1466-1482.
5. M. W. J. Layard and J. N. Arvesen (1978). Analysis of Poisson Data in Crossover Experimental Designs. Biometrics, Vol. 34, No. 3 (Sep., 1978), pp. 421-428, Published by: International Biometric Society.